Does Rallies show Form 4 insider transactions for REPL?

Yes. Rallies tracks REPL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is REPL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for REPL. It does not provide personalized investment advice.

REPL (Replimune Group, Inc.) Stock Analysis - Insider Trades

Replimune Group, Inc. (REPL) is a publicly traded Healthcare sector company. As of May 21, 2026, REPL trades at $5.10 with a market cap of $413.69M and a P/E ratio of -1.65. REPL moved +9.57% today. Year to date, REPL is -38.72%; over the trailing twelve months it is -43.85%. Its 52-week range spans $1.50 to $17.00. Analyst consensus is sell with an average price target of $2.25. Rallies surfaces REPL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading REPL stock inside the company?

Recent REPL insider activity includes Xynos Konstantinos sold 14.02K, Schwendenman Andrew sold 7.89K, Sarchi Christopher sold 8.63K, Astley-Sparke Philip sold 17.66K, and Patel Sushil sold 37.32K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

REPL Key Metrics

Key financial metrics for REPL
Metric	Value
Price	$5.10
Market Cap	$413.69M
P/E Ratio	-1.65
EPS	$-3.07
Dividend Yield	0.00%
52-Week High	$17.00
52-Week Low	$1.50
Volume	1.35K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-247.30M
Gross Margin	0.00%

Recent REPL Insider Trades

Xynos Konstantinos sold 14.02K (~$71.24K) on May 18, 2026.
Schwendenman Andrew sold 7.89K (~$40.10K) on May 18, 2026.
Sarchi Christopher sold 8.63K (~$43.82K) on May 18, 2026.
Astley-Sparke Philip sold 17.66K (~$89.70K) on May 18, 2026.
Patel Sushil sold 37.32K (~$189.61K) on May 18, 2026.

Latest REPL News

Replimune Presents 3-Year Survival and RP2 Phase 1 Safety Data at ASCO — Apr 27, 2026
Replimune Shares Plunge 64% After FDA Rejects RP1 Melanoma Therapy, Plans Layoffs — Apr 13, 2026
Replimune Shares Rally 43.6% as Loss Estimates Narrow for 2026-27 — Mar 10, 2026

REPL Analyst Consensus

7 analysts cover REPL: 0 strong buy, 0 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is sell. Average price target: $2.25.

Common questions about REPL

Who is trading REPL stock inside the company?: Recent REPL insider activity includes Xynos Konstantinos sold 14.02K, Schwendenman Andrew sold 7.89K, Sarchi Christopher sold 8.63K, Astley-Sparke Philip sold 17.66K, and Patel Sushil sold 37.32K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for REPL?: Yes. Rallies tracks REPL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is REPL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for REPL. It does not provide personalized investment advice.